Hepathrombin

Heparin Sodium, the active ingredient in Hepathrombin, is an anticoagulant presented as a cutaneous formulation for subcutaneous administration. It is employed to prevent and treat thromboembolic conditions by inhibiting clot formation in patients at risk, such as those undergoing surgery or receiving dialysis.

GNH USA supplies Hepathrombin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Hepathrombin (heparin sodium) acts on the coagulation cascade to reduce clot formation in several clinical settings. - Deep vein thrombosis prophylaxis: helps prevent clot formation after orthopedic or abdominal surgery. - Pulmonary embolism prevention: reduces the risk of embolic events in high‑risk medical patients. - Acute coronary syndrome management: supports anticoagulation during myocardial infarction treatment. - Hemodialysis circuit anticoagulation: maintains patency of extracorporeal blood circuits during renal replacement therapy. - Cardiopulmonary bypass: provides systemic anticoagulation during heart‑lung machine use.

Heparin sodium may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Local bruising or hematoma at injection site. - Minor bleeding from gums or nose. - Mild thrombocytopenia. - Injection site erythema or itching. - Transient elevation of liver enzymes.

Serious or Rare Side Effects: - Heparin‑induced thrombocytopenia (HIT). - Major hemorrhage, including intracranial or gastrointestinal bleeding. - Allergic anaphylactoid reactions. - Spontaneous spinal or epidural hematoma. - Severe thrombocytopenia with platelet count <20,000/µL.

When using Hepathrombin, clinicians should consider several safety measures. - Renal impairment: adjust monitoring as clearance may be reduced. - Hepatic disease: observe for altered coagulation parameters. - Concomitant antiplatelet or anticoagulant therapy: increase risk of bleeding. - Recent surgery or trauma: assess bleeding risk before administration. - Pregnancy and lactation: use only if clearly needed, after risk‑benefit evaluation. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Heparin sodium can interact with several drug classes, influencing its anticoagulant effect.

Major Interactions (Avoid): - Direct thrombin inhibitors (e.g., dabigatran): additive anticoagulation may cause severe bleeding. - Vitamin K antagonists (e.g., warfarin): synergistic effect increases hemorrhagic risk. - Antiplatelet agents (e.g., clopidogrel, aspirin): potentiate bleeding complications.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase minor bleeding. - Glycoprotein IIb/IIIa inhibitors: require careful coagulation monitoring. - Certain antibiotics (e.g., quinolones): can affect platelet function and increase bleeding tendency.